FDA sets up centre to improve quality of compounded drugs

Generics/General | Posted 24/01/2020 post-comment0 Post your comment

The US Food and Drug Administration (FDA) has established a Center of Excellence to improve the quality of compounded drugs, which are created by combining two or more drugs and are not FDA-approved.

150 AA010692

Compounding is the creation of a drug to meet the needs of a patient by combining of processing ingredients. Compounded drugs can, for example, be made from mixing two or more drugs and are used by patients whose needs cannot be met by FDA-approved drug.

Compounded drugs can be essential for patients with unique medical needs but, because they are not approved by FDA, are associated with efficacy and safety concerns.

In a statement last year [1], the Administration outlined plans to work with industry to reduce the risks associated with these products. In a recent follow-up, FDA has announced the establishment of a new Center of Excellence to improve the quality of compounded drugs.

Compounded drugs are often produced by outsourcing facilities, the number of which has increased since the passage of the Drug Quality and Security Act in 2013. Inspections of some outsourcing facilities have revealed concerning practices, in some cases even leading to product recalls and enforcement action.

The FDA’s new ‘Compounding Quality Center of Excellence’ will provide educational programmes for outsourcing facilities to help improve the quality of the products they produce.

Director of FDA’s Center for Drug Evaluation and Research Dr Janet Woodcock commented on the voluntary programme: ‘By providing comprehensive, accessible learning tools, we will support outsourcing facilities in reliably producing high-quality compounded products that meet FDA’s standards […] This initiative will provide an increased awareness and understanding of common issues and provide innovative ways to address challenges outsourcing facilities may face’.

The Center will be managed by Deloitte and will offer in-person and online training; a conference to allow exchange between outsourcing facilities, stakeholders and FDA; and market research to identify the key issues faced by facilities.

In-person training will begin in March and will focus on current good manufacturing practice (cGMP) and FDA policies. Specific topics for the training will include sterile compounding, environmental monitoring and proper cleanroom design.

Related articles
US and EU sign milestone mutual recognition agreement

FDA generics approvals increasing but not for at-risk generics

Safety of generics in US questioned

Reference
1. GaBI Online - Generics and Biosimilars Initiative. FDA pledges to improve quality of compounded drugs [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 January 24]. Available from: www.gabionline.net/Guidelines/FDA-pledges-to-improve-quality-of-compounded-drugs

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. 

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

Source: US FDA

comment icon Comments (0)
Post your comment
Related content
FDA reaches 100 generic approvals
53 MD002445
Generics/General Posted 12/11/2021
New five-year medicines agreements in Australia
24-AA011041
Generics/General Posted 24/09/2021
Generics applications under review by EMA – July 2021
EMA logo 2 V13F14
Generics/General Posted 23/07/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010